Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Efficacy, Safety and Treatment Satisfaction of Once Weekly Tirzepatide in Obese Type 2 Diabetic Patients at a Tertiary Care Centre
Lead sponsor
Asset
Tirzepatide
Subcutaneous · GLP-1 / GIP dual
Listed sites
0
Recruiting sites
-
Estimated enrollment
52
Study population
Obesity / overweight, Type 2 diabetes
Eligibility highlights
•BMI ≥25•HbA1c ≥7%
Primary endpoint
-
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Inclusion criteria
1. Male and female patients aged 30 to 80 years with diagnosed Type 2 Diabetes Mellitus.
2. Uncontrolled diabetes with HbA1c ≥ 7.0%.
3. Obesity defined as Body Mass Index (BMI) ≥ 25 kg/m² (Asian population threshold) or waist circumference > 90 cm in men or > 80 cm in women.
4. History of taking oral antidiabetic drugs (OADs) for > 1 year.
Exclusion criteria
1. Patients currently or previously taking GLP-1 receptor agonists or weight loss medications.
2. Patients currently receiving insulin therapy.
3. Patients taking DPP-4 inhibitors.
4. Pregnant or lactating females.
Endpoints (0)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
No endpoints recorded for this trial.
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.